Detection of Genes Modifying Sensitivity to Proteasome Inhibitors Using a shRNA Library in Breast Cancer
Final rept. 15 Feb 2006-14 Feb 2009
COLD SPRING HARBOR LAB NY
Pagination or Media Count:
By virtue of their accumulated genetic alterations, tumor cells may acquire vulnerabilities that create opportunities for therapeutic intervention. We have devised a massively parallel strategy for screening short hairpin RNA shRNA collections for stable loss-offunction phenotypes. We assayed from 6000 to 20,000 shRNAs simultaneously to identify genes important for the proliferation and survival of five cell lines derived from human mammary tissue. Lethal shRNAs common to these cell lines targeted many known cell-cycle regulatory networks. Cell line-specific sensitivities to suppression of protein complexes and biological pathways also emerged, and these could be validated by RNA interference RNAi and pharmacologically. These studies establish a practical platform for genome-scale screening of complex phenotypes in mammalian cells and demonstrate that RNAi can be used to expose genotype-specific sensitivities. We are applying these methods to study the drug Bortezomib Velcade. Velcade is the first targeted therapeutic to the proteasome approved by the FDA for treatment against multiple myeloma and is currently in phase II clinical trials for breast and lung cancers. We are identifying genes that mediate resistance against Velcade that could serve as potential drug targets.
- Anatomy and Physiology